Nuclear fusion and medical isotope developer Shine has completed the acquisition of Lantheus Holdings’ SPECT business, naming Michael Rossi as CEO of Shine SPECT USA.
The acquisition encompasses Lantheus' North Billerica, MA, SPECT manufacturing facility and portfolio of diagnostic radiopharmaceuticals, including TechneLite (technetium-99m [Tc-99m] generator), Cardiolite (Tc-99m Sestamibi for injection), Neurolite (Tc-99m Bicisate for injection), and xenon (Xe-133) gas agent for pulmonary ventilation and perfusion scans. Terms of the deal were not disclosed.
With Shine's lutetium-177 (Lu-177) production facilities, the acquisition positions Shine to deliver an integrated radioisotope supply chain, the company noted, adding that its Chrysalis facility under development in Janesville, WI, will produce molybdenum-99 (Mo-99), the parent isotope that decays into Tc-99m.
Now CEO of Shine SPECT USA, Rossi served as president and CEO of Y-mAbs Therapeutics, with previous assignments at Advanced Accelerator Applications, GE HealthCare, and Jubilant Radiopharma. He currently serves on the board of directors for Nucleus RadioPharma.
